Ibrutinib

別名:PCI-32765

イブルチニブ (Ibrutinib (PCI-32765)) は、無細胞アッセイで IC50 が 0.5 nM の強力で選択性の高い Brutons チロシンキナーゼ (Brutons tyrosine kinase, Btk) 阻害剤であり、Bmx, CSK, FGR, BRK, HCKに対しても阻害活性を持ちます。 EGFR, Yes, ErbB2, JAK3 に対しては前者より比較的弱い活性を持ちます。イブルチニブは、P13I を含む一連の PROTAC の合成における Btk リガンドとして適用できます。

Ibrutinib 化学構造

CAS No. 936563-96-1

サイズ 価格(税別) 在庫状況
10mM (1mL in DMSO) JPY 40800 国内在庫あり
JPY 25500 国内在庫あり
JPY 145500 国内在庫あり
JPY 220500 国内在庫あり
JPY 385500 国内在庫なし(納期7~10日)

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(511)

製品安全説明書

現在のバッチを見る: 純度: 99.98%
99.98

Ibrutinib と併用されることが多い化合物

Acalabrutinib (ACP-196)


Acalabrutinib (ACP-196) and Ibrutinib form a covalent bond with a cysteine residue (Cys481) in the BTK active site, leading to inhibition of BTK enzymatic activity. They are used as anti-neoplastic agents

Zanubrutinib


Both BTKi inhibitors treatment normalises lymphocyte subset frequency and reduces PD-1 expression on T cells.

Venetoclax (ABT-199)


Combined treatment leads to decrease in MCL1 protein and gives a synergistic effect

Jain N, et al. N Engl J Med. 2019 May 30;380(22):2095-2103.

Olaparib (AZD2281)


Ibrutinib plus olaparib additively inhibits MCL cell culture growth and impacts both cell survival and cell cycle regulation

Curtis AD, et al. Cancer Research. Vol. 77. 615 AMER ASSOC CANCER RESEARCH, 2017.

Osimertinib (AZD9291)


Ibrutinib reverses IL-6-induced osimertinib resistance via inhibition of Laminin α5/FAK signaling

Li L, et al. Commun Biol. 2022 Feb 23;5(1):155.

Ibrutinib 関連製品

Target Protein Ligand阻害剤の選択性比較

Cell Data

Cell Lines Assay Type Concentration Incubation Time 活性情報 PMID
human Rec1 cells Function assay 2.5 μM 6 h Inhibition of Lyn phosphorylation in human Rec1 cells at 2.5 uM incubated for 6 hrs by Western blotting method 25222877
human Ramos cells Function assay 1 h Inhibition of Btk in human Ramos cells assessed as inhibition of PLC-gamma2 phosphorylation at Tyr1217 after 1 hr by Western blot analysis, IC50=14 nM. 24915291
Sf9 cells Function assay 1 h Inhibition of LYN-A expressed in Sf9 cells after 60 mins by TR-FRET Assay, IC50=0.2 μM. 21958547
human DOHH2 cells Cytotoxic assay 72 h Cytotoxicity against human DOHH2 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50=0.41 μM. 24915291
human SU-DHL6 cells Cytotoxic assay 72 h Cytotoxicity against human SU-DHL6 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50=0.58 μM. 24915291
human WSU-NHL cells Cytotoxic assay 72 h Cytotoxicity against human WSU-NHL cells assessed as growth inhibition after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50=1.09 μM 24915291
human Pfeiffer cells Function assay 72 h Cytotoxicity against human Pfeiffer cells assessed as growth inhibition after 72 hrs by CellTiter-Glo luminescent cell viability assay, IC50=2 nM. 24915291
Sf9 cells Function assay 1 h Inhibition of human full-length BTK expressed in Sf9 cells using FAM-Srctide peptide as substrate after 60 mins by TR-FRET Assay, IC50=0.5 nM. 21958547
Sf9 insect cells Function assay 60 mins IC50 = 0.0003 μM 29146136
Sf9 insect cells Function assay 60 mins IC50 = 0.00034 μM 27912175
Sf9 insect cells Function assay 60 mins IC50 = 0.00034 μM 28432946
Sf9 insect cells Function assay 60 mins IC50 = 0.00034 μM 27956037
Sf9 cells Function assay 60 mins IC50 = 0.0004 μM 30006143
Sf9 cells Function assay 60 mins IC50 = 0.0005 μM 21958547
Ramos cells Function assay 1 h IC50 = 0.0005 μM 28280261
Sf9 cells Function assay 60 mins IC50 = 0.001 μM 30077608
Pfeiffer cells Cytotoxicity assay 72 h GI50 = 0.002 μM 24915291
B cells Function assay 1 h IC50 = 0.0046 μM 30290988
Sf9 insect cells Function assay 2 to 60 mins Ki = 0.0048 μM 28315597
Ramos cells Function assay 1 h IC50 = 0.0075 μM 24915291
Sf9 insect cells Function assay 60 mins IC50 = 0.008 μM 28315597
TMD8 cells Antiproliferative activity assay 72 h IC50 = 0.01 μM 29715023
CD19+ B cells Function assay 1 h IC50 = 0.012 μM 29457982
Sf9 insect cells Function assay 60 mins IC50 = 0.012 μM 28315597
Ramos cells Function assay 1 h IC50 = 0.014 μM 24915291
Sf9 insect cells Function assay 1 h IC50 = 0.0144 μM 29715023
Sf9 insect cells Function assay 60 mins IC50 = 0.0161 μM 29146136
HCC827 cells Antiproliferative activity assay 72 h IC50 = 0.039 μM 28734581
PC9 cells Function assay 72 h GI50 = 0.05 μM 28282122
Sf9 cells Function assay 60 mins IC50 = 0.1 μM 30006143
H3255 cells Function assay 72 h GI50 = 0.11 μM 28282122
BaF3 cells Function assay 72 h GI50 = 0.12 μM 26630553
BAF3 cells Antiproliferative activity assay 72 h GI50 = 0.12 μM 28956923
Sf9 insect cells Function assay 60 mins IC50 = 0.123 μM 28315597
Sf9 insect cells Function assay 60 mins IC50 = 0.146 μM 28315597
BAF3 cells Function assay 72 h GI50 = 0.16 μM 28282122
Sf9 cells Function assay 60 mins IC50 = 0.2 μM 21958547
MV4-11 cells Antiproliferative activity assay 72 h GI50 = 0.33 μM 26630553
MV4-11 cells Antiproliferative activity assay 72 h GI50 = 0.33 μM 28956923
DOHH2 cells Cytotoxicity assay 72 h GI50 = 0.41 μM 24915291
HCC827 cells Antiproliferative activity assay 96 h EC50 = 0.45 μM 28853575
SU-DHL6 cells Cytotoxicity assay 72 h GI50 = 0.58 μM 24915291
NCI-H1975 cells Antiproliferative activity assay 96 h EC50 = 0.64 μM 28853575
HEK293T cells Function assay 1 h IC50 = 0.9 μM 28280261
Ramos cells Antiproliferative activity assay 72 h IC50 = 0.92 μM 29715023
BA/F3 cells Antiproliferative activity assay 72 h IC50 = 1 μM 26258521
WSU-NHL cells Cytotoxicity assay 72 h GI50 = 1.09 μM 24915291
NCI-H1975 cells Function assay 72 h GI50 = 1.2 μM 28282122
NCI-H1975 cells Antiproliferative activity assay 72 h IC50 = 1.27 μM 28734581
Raji cells Antiproliferative activity assay 48 h IC50 = 1.49 μM 29567295
A431 cells Antiproliferative activity assay 96 h EC50 = 2.38 μM 28853575
BAF3 cells Antiproliferative activity assay 72 h GI50 = 2.5 μM 28956923
Ramos cells Antiproliferative activity assay 72 h IC50 = 5.14 μM 30006143
Ramos cells Antiproliferative activity assay 48 h IC50 = 5.14 μM 27956037
Ramos cells Antiproliferative activity assay 48 h IC50 = 5.88 μM 28432946
Ramos cells Antiproliferative activity assay 72 h IC50 = 6.62 μM 29146136
K562 cells Antiproliferative activity assay 48 h IC50 = 7.5 μM 30077608
HL60 cells Antiproliferative activity assay 48 h IC50 = 8 μM 30077608
Ramos cells Antiproliferative activity assay 48 h IC50 = 8.11 μM 27994736
Ramos cells Antiproliferative activity assay 48 h IC50 = 8.26 μM 29567295
BAF3 cells Cytotoxicity assay 72 h GI50 = 10 μM 26630553
BAF3 cells Antiproliferative activity assay 72 h GI50 = 10 μM 28956923
BAF3 cells Growth inhibition assay 72 h GI50 = 10 μM 28282122
NAMALWA cells Antiproliferative activity assay 72 h IC50 = 10.45 μM 29146136
Ramos cells Antiproliferative activity assay 48 h IC50 = 12.6 μM 27912175
Raji cells Antiproliferative activity assay 48 h IC50 = 14.2 μM 30077608
Raji cells Antiproliferative activity assay 48 h IC50 = 15.2 μM 27994736
MIAPaCa2 cells Cytotoxicity assay 3 days IC50 = 16.6 μM 27077228
HeLa cells Cytotoxicity assay 3 days IC50 = 16.8 μM 27077228
Raji cells Antiproliferative activity assay 48 h IC50 = 19.3 μM 27912175
Raji cells Antiproliferative activity assay 48 h IC50 = 19.3 μM 28432946
Raji cells Antiproliferative activity assay 72 h IC50 = 19.5 μM 30006143
Raji cells Antiproliferative activity assay 48 h IC50 = 19.5 μM 27956037
NAMALWA cells Antiproliferative activity assay 72 h IC50 = 19.6 μM 30006143
A2780 cells Cytotoxicity assay 3 days EC50 = 20.1 μM 27077228
Raji cells Antiproliferative activity assay 72 h IC50 = 20.88 μM 29146136
A549 cells Antiproliferative activity assay 72 h IC50 = 21.79 μM 28734581
SW480 cells Cytotoxicity assay 3 days IC50 = 25.6 μM 27077228
Ramos cells Cytotoxicity assay 24 h IC50 = 28.7 μM 28274675
sf9 cells Function assay IC50 = 0.0003 μM 27994736
MV411 cells Growth inhibition assay GI50 = 0.25 μM 28315597
M07e cells Growth inhibition assay GI50 = 0.59 μM 28315597
SU-DHL-2 cells Growth inhibition assay GI50 = 0.64 μM 28315597
Pfeiffer cells Growth inhibition assay GI50 = 1.6 μM 28315597
U937 cells Growth inhibition assay GI50 = 2.9 μM 28315597
NB4 cells Growth inhibition assay GI50 = 3 μM 28315597
Ramos cells Growth inhibition assay GI50 = 3.4 μM 28315597
SKM1 cells Growth inhibition assay GI50 = 3.6 μM 28315597
U2932 cells Growth inhibition assay GI50 = 4.4 μM 28315597
OCI-AML3 cells Growth inhibition assay GI50 = 9.2 μM 28315597
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明 イブルチニブ (Ibrutinib (PCI-32765)) は、無細胞アッセイで IC50 が 0.5 nM の強力で選択性の高い Brutons チロシンキナーゼ (Brutons tyrosine kinase, Btk) 阻害剤であり、Bmx, CSK, FGR, BRK, HCKに対しても阻害活性を持ちます。 EGFR, Yes, ErbB2, JAK3 に対しては前者より比較的弱い活性を持ちます。イブルチニブは、P13I を含む一連の PROTAC の合成における Btk リガンドとして適用できます。
Targets
BTK [1]
(Cell-free assay)
BLK [1]
(Cell-free assay)
Bmx [1]
(Cell-free assay)
CSK [1]
(Cell-free assay)
FGR [1]
(Cell-free assay)
もっとクリックする
0.5 nM 0.5 nM 0.8 nM 2.3 nM 2.3 nM
In Vitro
In vitro

Ibrutinib shows the potent and irreversible inhibitory effect and selectivity for Btk enzymatic activity. In BCR pathway-activated DOHH2 cell line, Ibrutinib inhibits autophosphorylation of Btk, phosphorylation of Btk's physiological substrate PLCγ, and phosphorylation of further downstream kinase, ERK with IC50 of 11 nM, 29 nM and 13 nM, respectively. [1] Ibrutinib exhibits a significant dose-dependent and time-dependent induction of cytotoxicity in chronic lymphocytic leukemia (CLL) cells. In addition, Ibrutinib induces cell death depending on caspase pathway activation and antagonizes the ability of CLL cells to proliferate after TLR signaling. [2] A recent study shows that Ibrutinib inhibits BCR-activated primary B cell proliferation with IC50 of 8 nM and results in inhibition of TNFα, IL-1β and IL-6 production in primary monocytes with IC50 of 2.6 nM, 0.5 nM and 3.9 nM, respectively. [3]

Kinase Assay Kinase Assays
In vitro kinase IC50 values are measured using 33P filtration binding assay after 1 hour incubation of kinase, 33P-ATP, Ibrutinib, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays are performed at Reaction Biology.
細胞実験 細胞株 Chronic lymphocytic leukemia (CLL) cells
濃度 0.01-100 μM
反応時間 48 hours
実験の流れ

MTT (3'[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assays are performed to determine cytotoxicity. Briefly, cells (CLL B cells or healthy volunteer T cells or NK cells) are incubated for 48 hours with different concentrations of Ibrutinib, or vehicle control. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. Dimethyl sulfoxide is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed with Expo-ADC32 software package. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis includes the addition of 100μM Z-VAD.

実験結果図 Methods Biomarkers 結果図 PMID
Western blot pEGFR(Tyr1068) / EGFR pBTK / pPLCγ2 / pAKT / pERK / pJNK 28061447
Immunofluorescence CD11b COX-2 30231870
ELISA hTNFα IL-10 26627823
In Vivo
In Vivo

In a collagen-induced arthritis model, Ibrutinib significantly reduces clinical arthritis scores reflecting paw swelling and joint inflammation by inhibiting B-cell activation. In a MRL-Fas(lpr) lupus model, Ibrutinib reduces renal disease and autoantibody production. [1] In an adoptive transfer TCL1 mouse model of CLL, Ibrutinib (25 mg/kg/day) causes a transient early lymphocytosis, and delays CLL disease progression. [4]

動物実験 動物モデル MRL-Fas(lpr) lupus model and collagen-induced arthritis model.
投与量 ≤50 mg/kg
投与経路 Administered via p.o.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06084923 Not yet recruiting
Chronic Lymphocytic Leukemia
Gruppo Italiano Malattie EMatologiche dell''Adulto
December 2023 --
NCT05694312 Recruiting
Autoimmune Hemolytic Anemia|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Monoclonal B-Cell Lymphocytosis CLL-Type
Gruppo Italiano Malattie EMatologiche dell''Adulto
November 24 2023 Phase 2
NCT05782374 Recruiting
PCNSL
IRCCS San Raffaele
August 10 2022 --
NCT05105841 Active not recruiting
Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)
AbbVie
November 8 2021 Phase 2

化学情報

分子量 440.5 化学式

C25H24N6O2

CAS No. 936563-96-1 SDF Download Ibrutinib SDFをダウンロードする
Smiles C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
保管

In vitro
Batch:

DMSO : 88 mg/mL ( (199.77 mM); 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : 8 mg/mL

Water : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください

よくある質問(FAQ)

質問1:
How to reconstitute the compound S2680 for in vivo studies?

回答
For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

Tags: Ibrutinib を買う | Ibrutinib ic50 | Ibrutinib 供給者 | Ibrutinib を購入する | Ibrutinib 費用 | Ibrutinib 生産者 | オーダーIbrutinib | Ibrutinib 化学構造 | Ibrutinib 分子量 | Ibrutinib 代理店